Flow Cytometric Assessment of Malignant Hematologic Disorders.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiparameter flow cytometry (MPF) is crucial for diagnosing hematologic malignancies.
• Recent advancements enhance MPF's role in identifying T-cell clonality and myelomonocytic dysplasia.
• Minimal/measurable residual disease (MRD) analysis is vital for B-lymphoblastic leukemia and increasingly important for myeloid malignancies.

Purpose of the Study:

• To highlight the expanding utility of MPF in hematologic disease diagnosis.
• To emphasize the role of emerging data analysis tools in leveraging complex MPF assays.
• To underscore the importance of MPF in managing hematologic malignancies.

Main Methods:

• Utilizing multiparameter flow cytometry (MPF) for diagnostic workup.
• Applying recently developed tools for T-cell clonality and myelomonocytic dysplasia detection.
• Implementing MRD analysis in the management of B-lymphoblastic leukemia and myeloid malignancies.

Main Results:

• MPF effectively detects T-cell clonality and myelomonocytic dysplasia.
• MRD analysis is a critical component in managing B-lymphoblastic leukemia and shows promise in myeloid malignancies.
• Increasing complexity of MPF assays necessitates advanced data analysis tools.

Conclusions:

• MPF is indispensable for diagnosing hematologic malignancies.
• Emerging analytical tools are essential for maximizing the benefits of complex MPF assays.
• MPF plays a key role in both diagnosis and disease monitoring of hematologic cancers.